Sign in
Active, not recruitingPhase 2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

Key facts

Who runs it
ModernaTX, Inc.
Where
Canada8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
366 people enrolled
Started
29 Apr 2026
Expected to end
9 Nov 2028
Type of study
Interventional, 2 groups
Treatments tested
  • mRNA-1982
  • Placebo
Record updated
3 August 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening
  • Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Who cannot take part

  • Received treatment for Lyme disease within the prior 3 months
  • Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease
  • Had a tick bite within 4 weeks prior to Day 1; Note: Additional inclusion/exclusion criteria may apply, per protocol
  • History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic
  • Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.

The 2 groups in the trial

  • Dose-finding PhaseTreatment being tested

    Participants will receive mRNA-1982 or placebo as an intramuscular injection.

    Treatment: mRNA-1982 and Placebo

  • Booster PhaseTreatment being tested

    Participants will receive mRNA-1982 (as a booster) or placebo as an intramuscular injection.

    Treatment: mRNA-1982 and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
Record updated
3 August 2026